CLINICAL_TRIALS
trial_result
· 2017-10-27
Clinical Trial Update: Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis. [Phase 3]
Summary
A Phase 3 trial comparing Secukinumab to Fumaderm in adults with moderate-to-severe psoriasis has completed and results were posted in 2017.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2017-10-27